Stocks · News reference
Silexion Therapeutics Announces Preclinical Data Showing SIL204 Upregulated FAS And Downregulated HLA-G Across Three KRAS-Mutant Pancreatic And NSCLC Cell Lines
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 1:15 PM
- Checked
- Aug 4, 2026, 1:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per
Read original at benzingaNasdaq Surges 150 Points; US Inflation Rate Slows To 3.4% In July
US stocks rise, Nasdaq up 150 points. Dow up 0.13%, Nasdaq up 0.62%, S&P 500 up 0.35%. IT shares up 1.2%, healthcare down 0.9%. CPI rises 3.4%.
Read original at benzingaSilexion Therapeutics shares are trading lower after the company announced the pricing of its $2.5 million public offering of 3,846,161 shares at $0.65 per share.
Read original at benzinga